These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 23269286

  • 21. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC.
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [Abstract] [Full Text] [Related]

  • 22. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.
    Millar JS, Lassman ME, Thomas T, Ramakrishnan R, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Wagner JA, Holleran S, Obunike J, Liu Y, Aoujil S, Standiford T, Gutstein DE, Ginsberg HN, Rader DJ, Reyes-Soffer G.
    J Lipid Res; 2017 Jun; 58(6):1214-1220. PubMed ID: 28314859
    [Abstract] [Full Text] [Related]

  • 23. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study.
    Gotto AM, Moon JE.
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):955-63. PubMed ID: 23030283
    [Abstract] [Full Text] [Related]

  • 24. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
    Cannon CP, Dansky HM, Davidson M, Gotto AM, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P, DEFINE investigators.
    Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins.
    Di Bartolo BA, Nicholls SJ, Bao S, Rye KA, Heather AK, Barter PJ, Bursill C.
    Atherosclerosis; 2011 Aug; 217(2):395-400. PubMed ID: 21571275
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Anacetrapib as a potential cardioprotective strategy.
    Di Bartolo BA, Nicholls SJ.
    Drug Des Devel Ther; 2017 Aug; 11():3497-3502. PubMed ID: 29263647
    [Abstract] [Full Text] [Related]

  • 34. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.
    Castro-Perez J, Briand F, Gagen K, Wang SP, Chen Y, McLaren DG, Shah V, Vreeken RJ, Hankemeier T, Sulpice T, Roddy TP, Hubbard BK, Johns DG.
    J Lipid Res; 2011 Nov; 52(11):1965-73. PubMed ID: 21841206
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Trials and Tribulations of CETP Inhibitors.
    Tall AR, Rader DJ.
    Circ Res; 2018 Jan 05; 122(1):106-112. PubMed ID: 29018035
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.